Last reviewed · How we verify

Engensis (VM202) — Competitive Intelligence Brief

Engensis (VM202) (Engensis (VM202)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plasmid DNA therapeutic; angiogenic agent. Area: Cardiovascular; Regenerative Medicine.

phase 3 Plasmid DNA therapeutic; angiogenic agent Hepatocyte growth factor (HGF) pathway; c-Met receptor Cardiovascular; Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Engensis (VM202) (Engensis (VM202)) — Helixmith Co., Ltd.. VM202 is a plasmid DNA therapeutic that encodes hepatocyte growth factor (HGF) to promote angiogenesis and tissue repair in ischemic tissues.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Engensis (VM202) TARGET Engensis (VM202) Helixmith Co., Ltd. phase 3 Plasmid DNA therapeutic; angiogenic agent Hepatocyte growth factor (HGF) pathway; c-Met receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plasmid DNA therapeutic; angiogenic agent class)

  1. Helixmith Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Engensis (VM202) — Competitive Intelligence Brief. https://druglandscape.com/ci/engensis-vm202. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: